Prof. Dr. Schulz, Martin
Geschäftsführer Pharmazie, Deutsches Arzneiprüfungsinstitut e. V. (DAPI), Berlin (bis Dez. 2025)
- seit Nov. 2025 im Vorstand des Deutschen Arzneiprüfungsinstituts e. V. (DAPI)
- seit April 2019 Honorarprofessor an der Freien Universität Berlin, Institut für Pharmazie
- seit Januar 2009 Vorsitzender der Arzneimittelkommission der Deutschen Apotheker (AMK)
- seit April 2008 Geschäftsführer für den Bereich Arzneimittel der ABDA, der BAK und des DAV
- seit Juli 2005 Honorarprofessor der Goethe-Universität Frankfurt
- März 2002 - Dez. 2025 Geschäftsführer Pharmazie des Deutschen Arzneiprüfungsinstituts (DAPI)
- 2001 - 2005 Lehrauftrag Klinische Pharmazie an der Goethe-Universität Frankfurt
- 1993 Fachapotheker für Arzneimittelinformation
- 1992 - 2008 Stellvertretender Vorsitzender der Arzneimittelkommission der Deutschen Apotheker (AMK)
- 1989 Fachpharmakologe DGPT
- Oktober 1988 - März 2008 Leiter Zentrum für Arzneimittelinformation und Pharmazeutische Praxis (ZAPP) der ABDA
- 1988 Promotion in Pharmakologie zum Dr. rer. nat.
- Oktober 1984 - September 1988 Wissenschaftlicher Mitarbeiter am Pharmakologischen Institut und Institut für Rechtsmedizin, Universität Hamburg
- 1984 - 1986 Studium der Medizin (Universität Hamburg)
- 1983 - 1984 Apotheker, Krankenhaus St. Adolf-Stift, Reinbek
- Mai 1983 Approbation als Apotheker
- 1978 - 1982 Studium der Pharmazie (Universität Hamburg)
Publications
- Increasing use of non-statin and combination lipid-lowering therapies 2012–2025: a nationwide study
- Inhaler use and their carbon footprint in Germany: a 10-year analysis (2013–2022)
- 100 Millionen Pens jährlich in Deutschland – und dann in den Hausmüll?
- Temporal trends in the prescription of low‑dose antithrombotic and anti‑inflammatory therapies in Germany (2022–2024)
- 100 Million Pens a Year in Germany: And Then in the Trash?
- Fixkombinationen von Antihypertensiva auf dem deutschen Markt - Inklusive verfügbare Wirkstärken - Stand 15.03.2025
- Trends in Use of Antipsychotics in Germany 2014–2023: A Nationwide Population-Based Study (Posterpräsentation GAA)
- Glukoselösungen für den oGTT: Update 2024
- Trends in Use of Antipsychotics in Germany 2014–2023: A Nationwide Population-Based Study (Posterpräsentation ISPE)
- The utilization of discharge prescriptions in Germany - An overview for the years 2018–2021
- Use of fixed-dose combinations for cardiovascular indications from 2018 to 2023: a nationwide population-based study
- Declining rates of fixed-dose combination pills for hypertension in Germany from 2016 to 2023
- Hidden sodium in effervescent-tablet dietary supplements and over-the- counter drugs: a comparative cross-sectional study
- Impact of the COVID-19 pandemic on implementation of novel guideline-directed medical therapies for heart failure in Germany: a nationwide retrospective analysis
- Increased Demand for Pharmaceutical Drugs Containing Potassium Iodide In Connection with the Russia-Ukraine Conflict
- Auszeichnung als Top Downloaded Article 2021-2022
- Auszeichnung als Top Cited Article 2021-2022
- Assessment of the Prescriptions of Systemic Antibiotics in Primary Dental Care in Germany from 2017 to 2021: A Longitudinal Drug Utilization Study
- Trends in Ezetimibe Prescriptions as Monotherapy or Fixed-Dose Combination in Germany 2012–2021
- Use of fixed‑dose combination antihypertensives in Germany between 2016 and 2020: an example of guideline inertia
- Verordnungsqualität oraler Fluorchinolone in den deutschen Bundesländern 2014 bis 2019
- Utilization of drugs with reports on potential efficacy or harm on COVID-19 before, during, and after the first pandemic wave
- Utilization of drugs with reports on potential efficacy or harm on COVID-19 before, during, and after the first pandemic wave (1)
- Quality Appraisal of Ambulatory Oral Cephalosporin and Fluoroquinolone Use in the 16 German Federal States from 2014–2019
- Wie wirken Generikaquoten? Eine Analyse am Beispiel der HIV Infektion
- Infliximab And Etanercept Biosimilars And Originators: Learnings From Regional Market Dynamics In Germany
- Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany
- Impact of angiotensin receptor blocker product recalls on antihypertensive prescribing in Germany
- “Dear Doctor” Warning Letter (Rote-Hand-Brief) on Hydrochlorothiazide and Its Impact on Antihypertensive Prescription
- Changes in utilization of antihypertensive drugs following angiotensin receptor blocker product recalls in Germany
- Impact On Antihypertensive Prescribing After The Dear Healthcare Professional Letter On Increased Risk Of Skin Cancer Related To Hydrochlorothiazide
- Post-mortem analysis of prescription opioids - A follow-up examination by LC–MS/MS with focus on fentanyl
- The frequency of photosensitizing drug dispensings in Austria and Germany: A correlation with their photosensitizing potential based on published literature.
- Comparing outpatient oral antibiotic use in Germany and the Netherlands from 2012 to 2016
- Oral Antibiotics in Germany and the Netherlands in Primary Care from 2012 – 2016: A Comparison
- Temporal synchrony between drug dispensings and adverse drug events? The example of statins & rhabdomyolysis and metamizole or clozapine & agranulocytosis
- In search of a standard when analyzing medication adherence in patients with heart failure using claims data: a systematic review.
- Evaluation of pharmaceutical concerns in Germany: frequency and potential reasons
- Medication adherence and persistence according to different antihypertensive drug classes: A retrospective cohort study of 255,500 patients
- Can claims data help validating drug risk signals? A case report
- Ad hoc-Auswertungen des DAPI. Dokumentation pharmazeutischer Bedenken in Berlin
- Hepatitis C - Neue Wirkstoffe im Vergleich
- Adherence to Disease Modifying Drugs among Patients with Multiple Sclerosis in Germany: A Retrospective Cohort Study
- Rabattverträge nach § 130a Abs. 8 SGB V: Das Instrument der pharmazeutischen Bedenken
- Innovative Hepatitis-C-Arzneimittel - Was der Zusatznutzen wirklich kostet
- Rebate contracts: reasons not to substitute
- Innovative Arzneimittel bei Hepatitis C - Was kostet der Zusatznutzen?
- Pharmazeutische Bedenken. Die zehn häufigsten Wirkstoffe in Niedersachsen.
- Dosage strength is associated with medication persistence with Ginkgo biloba drug products: a cohort study of ambulatory drug claims data in Germany
- DAPI-Zahlen aus Berlin. Die 10 häufigsten Wirkstoffe mit pharmazeutischen Bedenken
- Adherence to antihypertensives: feasibility of two self-report instruments to investigate medication-taking behaviour in German community pharmacies.
- DAPI-Zahlen aus Rheinland-Pfalz. Die 10 häufigsten Wirkstoffe mit pharmazeutischen Bedenken
- Medication persistence with ginkgo biloba drugs of different dosage strengths - Persistenz bei Ginkgo biloba-Arzneimitteln unterschiedlicher Wirkstärke.
- Effect of switching branded risedronate to branded or generic alendronate on medication compliance with weekly bisphosphonates: a cohort study utilizing the dapi prescription claims database
- Switching the pharmaceutical dosage form of extended-release valproate is associated with therapeutic modification of antiepileptic therapy
- Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: A cohort study.
- Treatment duration (persistence) of basal insulin supported oral therapy (BOT) in Type-2 diabetic patients: comparison of insulin glargine with NPH insulin.
- Comparison of different ways of calculation (DDD vs. SPC) to determine persistence and compliance with beta blockers in the DAPI database.
- Generic switch after ramipril patent expiry is not associated with decreased pharmacy refill compliance: a retrospective study using the DAPI database.
- Association between generic substitution of valproate and therapeutic modification of antiepileptic therapy – a cohort study with time-dependent exposure utilizing the DAPI ambulatory drug claims data
- Strategien zur Verbesserung der Einnahmetreue von Medikamenten.
- Verbesserung der Therapietreue bei Hypertonikern - eine Aufgabe für den Apotheker
- Impact of rebate contract legislation on generic substitution of valproate – a retrospective study of ambulatory drug dispensing in the DAPI database
- Effect of generic switch on pharmacy refill compliance after ramipril patent expiry – a retrospective study using the DAPI database
- Incidence of thyroid hormone therapy in patients treated with sorafenib or sunitinib
- Persistence with basal supported oral therapy - comparison of insulin glargine versus NPH insulin.
- Utilizing claims data to assess persistence with antidepressants.
- Persistence with basal supported oral therapy - comparison of insulin glargine versus NPH insulin. (1)
- Pharmacy refill adherence with antidepressants.
- Switching from branded alendronate or risedronate to generic alendronate: effect on persistence with bisphosphonate therapy in Germany
- Switching from branded alendronate or risedronate to generic alendronate: effect on persistence with bisphosphonate therapy in Germany (1)
- Beeinflusst die Umstellung von Risedronat oder Alendronat Originalprodukten auf Generika die Compliance (Persistenz)?
- Impact of risk communications and market withdrawals on prescribing of cyclooxygenase-2 inhibitors and non-selective nonsteroidal anti-inflammatory drugs
- Aktuelle Verordnungen von COX-2-Hemmern in Deutschland
- Non-Compliance – das unterschätzte Problem: Neue Möglichkeiten der Erfassung über Datenbankanalysen
- Methoden der Datenbank-basierten Persistenz- und Apotheken-basierten Adhärenz-Erfassung am Beispiel von Antihypertensiva
- Persistence under treatment with ramipril
- The Value of Access to Pharmacy Claims Data for Healthcare Market Analyses
- Differences In Persistence Rates Between Various Classes Of Antihypertensives In Diabetic Patients
- Epidemiologische Analyse der Compliance
- Zielpreise für Leitsubstanzen: Verantwortungsteilung zwischen Arzt und Apotheker
- Versorgungsforschung: Persistenz und Compliance bei Antihypertensiva
- Prescribing of COX-2 inhibitors in Germany after safety warnings and market withdrawals
- Arzneimittelversorgung – Coxibverordnungen nach Marktrücknahmen und Risikomeldungen
- Statine – Verordnungsanalyse und Praxistipps